Suppr超能文献

选择与 HIV-1 gp41 的第一个七肽重复序列相对应的肽融合抑制剂,可鉴定出两种遗传途径,使 gp41 的第一个和第二个七肽重复序列(HR1 和 HR2)对应的肽融合抑制剂产生交叉耐药性。

Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41.

机构信息

Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, HFM-466, Bldg. 29, Room 532, 29 Lincoln Dr., Bethesda, MD 20892, USA.

出版信息

J Virol. 2011 Dec;85(24):12929-38. doi: 10.1128/JVI.05391-11. Epub 2011 Oct 12.

Abstract

We generated four HIV-1 cultures that are resistant to a peptide fusion inhibitor corresponding to the first heptad repeat of gp41 in order to study mechanisms of resistance and gain insights into envelope glycoprotein-mediated membrane fusion. Two genetic pathways emerged that were defined by acquisition of a specific mutation in either the first or second heptad repeat region of gp41 (HR1 or the HR2, respectively). Each pathway was enriched in mutations that clustered in either HR2 and V3 or in HR1 and residues in or near CD4 contact sites. The gp41 mutations in both pathways not only accounted for resistance to the selecting HR1 peptide but also conferred cross-resistance to HR2 peptide fusion inhibitors and enhanced the stability of the six-helix bundle formed by the self-assembly of HR1 and HR2. The gp120 mutations alone enhanced fusion but did not appear to directly contribute to resistance. The implications of these findings for resistance mechanisms and regulation of envelope-mediated fusion are discussed.

摘要

我们生成了四种对对应于 gp41 第一七肽重复的肽融合抑制剂具有抗性的 HIV-1 培养物,以便研究抗性机制并深入了解包膜糖蛋白介导的膜融合。出现了两种遗传途径,其特征是在 gp41 的第一或第二七肽重复区(分别为 HR1 或 HR2)中获得特定突变。每条途径都富含突变,这些突变聚集在 HR2 和 V3 或 HR1 以及 CD4 接触位点内或附近的残基中。两条途径中的 gp41 突变不仅解释了对选择的 HR1 肽的抗性,而且还赋予了对 HR2 肽融合抑制剂的交叉抗性,并增强了由 HR1 和 HR2 自身组装形成的六螺旋束的稳定性。单独的 gp120 突变增强了融合,但似乎并没有直接导致抗性。这些发现对包膜介导融合的抗性机制和调控的影响将进行讨论。

相似文献

5
Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.
J Biol Chem. 2012 Mar 9;287(11):8297-309. doi: 10.1074/jbc.M111.324483. Epub 2012 Jan 10.
8
Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.
Antimicrob Agents Chemother. 2005 Mar;49(3):1113-9. doi: 10.1128/AAC.49.3.1113-1119.2005.

引用本文的文献

1
Structure and Interactions of HIV-1 gp41 CHR-NHR Reverse Hairpin Constructs Reveal Molecular Determinants of Antiviral Activity.
J Mol Biol. 2024 Aug 15;436(16):168650. doi: 10.1016/j.jmb.2024.168650. Epub 2024 Jun 10.
2
SARS-CoV-2 Fusion Peptide Conjugated to a Tetravalent Dendrimer Selectively Inhibits Viral Infection.
Pharmaceutics. 2023 Dec 17;15(12):2791. doi: 10.3390/pharmaceutics15122791.
4
A targeted covalent small molecule inhibitor of HIV-1 fusion.
Chem Commun (Camb). 2021 May 6;57(37):4528-4531. doi: 10.1039/d1cc01013a.
7
Characterization of resistance to a potent D-peptide HIV entry inhibitor.
Retrovirology. 2019 Oct 22;16(1):28. doi: 10.1186/s12977-019-0489-7.
10
Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
J Biol Chem. 2018 Aug 17;293(33):12703-12718. doi: 10.1074/jbc.RA118.003538. Epub 2018 Jun 21.

本文引用的文献

1
2
Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
Antiviral Res. 2010 Aug;87(2):179-86. doi: 10.1016/j.antiviral.2010.04.011. Epub 2010 May 8.
5
Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding.
PLoS Pathog. 2009 Nov;5(11):e1000674. doi: 10.1371/journal.ppat.1000674. Epub 2009 Nov 26.
6
Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation.
PLoS Pathog. 2009 Sep;5(9):e1000585. doi: 10.1371/journal.ppat.1000585. Epub 2009 Sep 18.
10
Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency.
Protein Sci. 2008 Apr;17(4):633-43. doi: 10.1110/ps.073307608.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验